Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

समान संसाधन

• BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
  द्वारा: Mahlangu, Johnny, और अन्य
  प्रकाशित: (2020)
• BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
  द्वारा: Santoro, Cristina, और अन्य
  प्रकाशित: (2020)
• Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
  द्वारा: Kavakli, K, और अन्य
  प्रकाशित: (2015)
• BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review
  द्वारा: Mahlangu, Johnny N., और अन्य
  प्रकाशित: (2018)
• Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
  द्वारा: Pocoski, Jennifer, और अन्य
  प्रकाशित: (2016)